Inhibitors of the human immunodeficiency virus type 1 protease represent a promising class of antiviral drugs for the treatment of AIDS, and several are now in clinical trials. Here, we report the in vitro selection of viral variants with decreased sensitivity to a C2-symmetric protease inhibitor (A-77003). We show that a single amino acid substitution (Arg to Gln or Lys) at position 8 of the protease results in a substantial decrease in the inhibitory activity of the drug on the enzyme and a comparable increase in viral resistance. These findings, when analyzed by using the three-dimensional structure of the protease-drug complex, provide a strategic guide for the future development of inhibitors of the human immunodeficiency virus type 1 protease.
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Several antiviral agents, targeting the reverse transcriptase of the human immunodeficiency virus type 1 (HIV-1), have been developed for the treatment of AIDS. Since these drugs have limited clinical benefit due in part to the development of viral resistance (7, 10, 11, 15-17, 22, 24, 25, 27) , inhibitors against other HIV-1 targets are urgently needed. The HIV-1 aspartic protease is a logical target for rational drug screening and design (5) . This viral enzyme functions as a homodimer in which the two subunits are related by a twofold (C2) axis of symmetry (14, 20, 29) . A single enzyme active site is formed at the interface between the subunits. Posttranslational processing of Gag and Pol polypeptides by the protease is required for viral maturation and infectivity. To date, numerous compounds that block protease function and inhibit HIV-1 replication in vitro have been identified (4, 6, 12, 13, 18, 21, 26, 28 (12, 13, 21) . Several of these compounds have shown favorable pharmacokinetic and toxicity profiles in animals, including A-77003, which has entered into phase 1 studies with HIV-1-infected individuals.
We began to examine HIV-1 resistance to A-77003 by growing NL4-3 (1), a virus derived from an infectious molecular clone (multiplicity of infection, 0.01 50% tissue culture infective dose per cell), in MT-4 cells (2 x 105/ml) in the presence of a subinhibitory concentration (0.02 ,uM) of A-77003. When viral replication (supernatant p24 antigen) was evident, the supernatant fluid was harvested and used to infect additional MT-4 cells in the presence of a higher concentration of A-77003. As summarized in Table 1 , this selection scheme was serially carried out for 19 passages using drug concentra-tions of up to 10 jiM. The cell pellet from each passage was stored at -80°C for sequencing studies. Viral populations from passages 4, 14, 17, and 19 along with the parental NL4-3 were each propagated, their titers were determined, and the populations were tested for sensitivity to A-77003. A-77003 sensitivity studies were performed with MT-4 cells and 500 50% tissue culture infective doses of each virus, and the inhibitory effect of the drug was assessed by measuring p24 antigen in the culture supernatant on day 4. As shown in Table   1 , a fourfold increase in ID50 was seen for the passage 14 virus (P14), while a 35-fold increase was observed for the passage 19 virus (P19), together with a substantial increase in ID90.
P14 and P19 were further characterized to determine the sequence changes responsible for the reduced sensitivity to A-77003. Although it is theoretically possible that alterations in other genomic regions could affect drug susceptibility, we focused on the protease-encoding region of pol as the most likely to account for the increased resistance. DNA was extracted from P14 and P19 and subjected to PCR using primers 5'-AGAAGAGAGCTCCAGGlTTTGGGGA A-3' (2166 to 2190) and 5'-GGCTTGAATTCITACTGGTA CAGTCT-3' (2566 to 2590). The The deduced amino acid sequences in Fig. 1 show that, compared with the parental NL4-3, 9 of 10 M13 clones derived from P14 contained an arginine-to-glutamine substitution at amino acid 8 of protease (R8Q). One clone (P14-10), lacking the R8Q mutation, had a valine-to-alanine substitution at position 82 (V82A) instead. Eight of 10 clones from P14 also contained a methionine-to-isoleucine substitution at position 46 (M461). Every M13 clone from P19 contained either the same R8Q substitution or a lysine substitution at the same position (R8K); every P19 clone also had the M461 mutation. In addition, several scattered substitutions were found in some clones between amino acids 49 and 80 of the protease (Fig. 1) .
The consistent changes at amino acids 8 and 46 suggest that these substitutions could be responsible for the increased resistance to A-77003. Arg-8 is highly conserved among all published sequences for HIV-1, HIV-2, and simian immunodeficiency virus proteases (8, 19) . In contrast, Ile-46 was seen in only one of 21 HIV-1 sequences but is found in all HIV-2 and simian immunodeficiency virus sequences (8, 19) .
To address whether these observed mutations were responsible for the increased resistance to A-77003, site-directed mutagenesis was performed on the infectious molecular clone pNL4-3. R8Q, R8K, and M46I mutants as well as an R8Q/ M46I double mutant were generated and reconstructed back into pNL4-3. A 7,018-bp SphI-BamHI fragment of NL4-3 was cloned into a pALTI (Promega, Madison, Wis.) vector, and the mutagenesis was conducted according to the manufacturer's instructions. The mutagenized fragment was then reconstructed back into pNL4-3, and infectious virus was obtained by electroporation of the clone into MT-4 cells (3). As shown in Fig. 2A , the R8Q mutant replicated less efficiently than the parental NL4-3, whereas the M461 virus grew well. Interestingly, the R8Q/M46I double mutant replicated efficiently, suggesting that the M46I mutation may compensate for the deleterious effect of the R8Q change. Likewise, with an additional base substitution at codon 8, the R8Q variant was further mutated to give rise to an R8K variant, which grew as efficiently as the parental virus ( Fig. 2A) .
Each of these mutant viruses was propagated, the titers were determined, and the viruses were tested for sensitivity to A-77003. As shown in Fig. 2B , the M461 mutant and the parental virus were equally sensitive to A-77003. However, the R8Q, R8K, and R8Q/M46I mutants were less sensitive, with approximate ID5( and ID(,( of 1.0 to 2.0 and 10 p.M, respectively, suggesting a 10-fold decrease in sensitivity to A-77003. Additional studies to determine whether the R8K/M461 double mutant and the scattered changes between amino acids 49 and 80 contribute to the increased resistance exhibited by P19 are in progress. Nevertheless, the data in Fig. 2B suggest that the R8Q and R8K mutations are each responsible for a substantial portion of the increased resistance to A-77003.
To confirm that the decrease in A-77003 sensitivity was mediated by changes in the inhibitory activity of the drug on the mutant proteases, the enzymes from NL4-3, R8Q, and M461 viruses were individually expressed and purified for determination of the inhibitory constant (K,) for A-77003. Each HIV-1 mutant protease was overexpressed in insoluble form in E. coli after arabinose induction. Following solubilization in 8 M urea, the samples were passed through a DE-52 cellulose (Whatman) column, dialyzed to remove urea, and affinity purified by elution through a Pepstatin A agarose (Pierce) column. Final purification of active fractions was accomplished by elution through an HD/M HPLC Poros column (Perspective Biosystems). Inhibition of HIV-l protease was measured by using the fluorogenic substrate DAB-CYL-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS as previously described (12, 13, 21) . Ki values were calculated by using equations for tight-binding inhibitors (our unpublished data). As shown in Fig. 3 , the Ki of NL4-3 protease for A-77003 was found to be 84 pM. A similar Ki (120 pM) was found for the M461 mutant protease; however, the Ki for the R8Q mutant protease was 2,700 pM, an approximately 32-fold increase compared with the parental protease. Therefore, we conclude that the R8Q mutation significantly decreased the protease inhibition by A-77003 whereas the M461 mutation had only a minimal effect. Similar Ki determinations are now in progress for the R8K, R8Q/M461, and R8K/M46I mutant proteases.
The crystal structure of A-77003 complexed with the wildtype protease shows that the aromatic pyridine groups at the distal ends of the drug interact closely with the arginine residue at position 8 of each subunit of the protease homodimer (Fig.  4, top) charge quadrupole electrostatic interactions, and similar types of interactions have been observed with protein-ligand binding (2). We have modelled the R8Q mutant into the crystal structure of the A-77003-protease complex (Fig. 4, bottom) . In this model, Gln-8 makes less extensive van der Waals contacts with the pyridine groups. In addition, the strength of the electrostatic interaction should be reduced owing to the subtractive effects of both the reduced positive charge of the amide side chain of glutamine and the greater distance dependence of the amide dipole-pyridine ring interaction. We be- Arg-8 in HIV-1 protease also plays a role in dimer stability, since it forms a favorable electrostatic interaction with Asp-129 from the other subunit (Fig. 4, top) (14, 20, 29) . This symmetric salt bridge is maintained in the A-77003 complex but is abolished in the R8Q mutant, which can at best form a hydrogen bond between Gln-8 and Asp-129. Thus, the inferior growth characteristics of the R8Q mutant in vitro may be a reflection of reduced enzyme stability. The restoration of wild-type replication kinetics for the R8Q/M461 double mutant is difficult to explain on structural grounds alone. Met-46 protrudes from the flap into the solvent and does not make contacts with A-77003 (our unpublished data), but it may play a role in binding the Gag and Pol polyprotein substrates (9) . Alternatively, the compensatory effect of the M461 mutation on virus growth may be due to a kinetic effect on protease activity by virtue of its position on the flap, where it may modulate flap dynamics.
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In conclusion, we have selected HIV-1 variants in vitro which have increased resistance to a protease inhibitor. Although other mutations may contribute, the R8Q and R8K mutations in the protease appear to be primarily responsible for the decrease in the inhibitory activity of the drug on the enzyme and the consequent increase in viral resistance. These findings are similar to what has been found for HIV-1 resistance to inhibitors of reverse transcriptase, in which a single amino acid substitution resulted in greater drug resistance (7, 10, 11, 15-17, 22, 24, 25, 27 
